The Sevoflurane study, understanding the effects of Sevoflurane to improve safety and outcome of cardiac surgery.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20447

Enrollment

Registered

2009-10-30

Start date

2009-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sevoflurane, Cardiac Surgery, Inflammation, Preconditioning

Interventions

Sevoflurane will be added to the blood cardioplegia mixture in the treatment cohort. The control-cohort will receive oxygen. Addition only when Heart-lungmachine is activated. Blook will be taken sev

Eligibility

Inclusion criteria

Inclusion criteria: 1. Acceptation for mitral valve surgery via sternotomy; 2. LV ejection fraction > 35%.

Exclusion criteria

Exclusion criteria: 1. Acceptation for minimal invasive valve surgery; 2. Use of systemic corticosteroids; 3. Inability to introduce coronary sinus catheter; 4. Inability to sign informed consent or less than 18 years old; 5. Emergency operations.

Design outcomes

Primary

Measure	Time frame
1. Factors related to the acute inflammatory response (IL-6, ICAM e.d.); 2. Factors likely involved in pathophysiology of I/R injury (cytokines); 3. Markers of myocardial injury (Trop/CK-MB).	—

Secondary

Measure	Time frame
1. Factors related to the acute inflammatory response (IL-6, ICAM e.d.); 2. Factors likely involved in pathophysiology of I/R injury (cytokines); 3. Markers of myocardial injury (Trop/CK-MB).	—

Contacts

Public ContactR.J.M. Klautz

Leiden University Medical Center (LUMC), Department of CardioThoracic Surgery, room D6-53, P.O. Box 9600

r.j.m.klautz@lumc.nl+31 (0)71 5264022

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)